At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Semaglutide (drug)
- How long the study runs
- Study runs about 1 month (dates as stated)
- About the drug or intervention
- Semaglutide — drug: This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 237,211
- Started
- 2026-05-12
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for overweight
- • Clinical study - 237,211 participants
- • The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with overweight
Where?
- • London - Novo Nordisk Investigational Site
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
OverweightObesity
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Initiation of semaglutide for weight management during the study period.
- ✓Age more than or equal to (≥) 18 at treatment initiation
- ✓Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one...
- ✓Other inclusion criteria as defined in the protocol are applicable.
Who cannot take part
- ✗Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management...
- ✗Bariatric surgery at baseline.
- ✗Diabetes at baseline.
- ✗Pregnancy at baseline.
See the full criteria
Inclusion Criteria:
* Initiation of semaglutide for weight management during the study period.
* Age more than or equal to (≥) 18 at treatment initiation
* Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.
* Other inclusion criteria as defined in the protocol are applicable.
Exclusion Criteria:
* Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
* Bariatric surgery at baseline.
* Diabetes at baseline.
* Pregnancy at baseline.
Where Is This Study? (1 UK site)
Novo Nordisk Investigational Site
London, United Kingdom
Data sourced from ClinicalTrials.gov · Last verified: 2026-09